Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01850823 · ClinicalTrials.gov registry record · Phase 3
Clinical Equivalence Study of Mometasone Nasal Spray
A Phase 3 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 3
- Development phase
- 880
- Enrollment target
NCT01850823: Completed Phase 3 study, sponsored by Actavis.
NCT01850823 is a Phase 3 study that has completed, run by Actavis. The registered enrollment target is 880 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01850823, a Phase 3 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 880 participants
- Enrollment target
Study Summary
A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare the Clinical Equivalence of Mometasone Nasal Spray (Watson Laboratories, Inc) with NASONEX® Nasal Spray (Schering Corporation) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
Primary Outcome
The Total Nasal Symptom Score Scale was used. Patients rated each of the following four symptoms on a scale from 0 to 3 : Nasal Congestion, Runny Nose, Sneezing, and Itchy Nose. Measurements were taken twice daily approximately 12 hours apart. 0= No symptom 1. Mild symptoms (sign/symptom present, minimal awareness, easily tolerated) 2. Moderate symptom (definite awareness of sign/symptom, bothersome but tolerable) 3. Severe symptom (sign/symptom hard to tolerate, causes interference with daily
Interventions
- DRUG placebo
- DRUG Mometasone Nasal Spray
- DRUG Mometasone nasal spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 880 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
What the finished NCT01850823 record still lists
NCT01850823 is an interventional study that assigns participants to a tested intervention. The registered 880 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01850823 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01850823 about?
NCT01850823 is a clinical study titled "Clinical Equivalence Study of Mometasone Nasal Spray". A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare the Clinical Equivalence of Mometasone Nasal Spray (Watson Laboratories, Inc) with NASONEX® Nasal Spray (Schering Corporation) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
What is the current status of trial NCT01850823?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 880 participants. The study started on 2013-02. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01850823?
The interventions under investigation include: placebo (DRUG), Mometasone Nasal Spray (DRUG), Mometasone nasal spray (DRUG).
Who is sponsoring clinical trial NCT01850823?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01850823's enrollment target sits among peer trials
880 367th of 2000 higher than 1,631 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05454280 · 880 participants · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
- NCT05525663 · 880 participants · NA
Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction
- NCT06580314 · 880 participants · Phase 3
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia